Aggressive Phenotypic and Genotypic Features in Pediatric and NF2-Associated Meningiomas: A Clinicopathologic Study of 53 Cases

2001/10/01 by Arie Perry, Caterina Giannini, Ravi Raghavan +10 · 26 citations
Medicine · #Meningioma and schwannoma management #Neurofibromatosis and Schwannoma Cases #Cerebral Venous Sinus Thrombosis

paper · doi:10.1093/jnen/60.10.994

Abstract

Pediatric and NF2-associated meningiomas are uncommon and poorly characterized in comparison to sporadic adult cases. In order to elucidate their molecular features, we analyzed MIB-1, progesterone receptor (PR), NF2, merlin, DAL-1, DAL-1 protein, and chromosomal arms 1p and 14q in 53 meningiomas from 40 pediatric/NF2 patients using immunohistochemistry and dual-color fluorescence in situ hybridization (FISH). Fourteen pediatric (42%) patients, including 5 previously undiagnosed patients, had NF2. The remaining 19 (58%) did not qualify. All 7 of the adult patients had NF2. Meningioma grading revealed 21 benign (40%), 26 atypical (49%), and 6 anaplastic (11%) examples. Other aggressive findings included high mitotic index (32%), high MIB-1 LI (37%), aggressive variant histology (e.g. papillary, clear cell) (25%), brain invasion (17%), recurrence (39%), and patient death (17%). FISH analysis demonstrated deletions of NF2 in 82%, DAL-1 in 82%, 1p in 60%, and 14q in 66%. NF2-associated meningiomas did not differ from sporadic pediatric tumors except for a higher frequency of merlin loss in the former (p = 0.020) and a higher frequency of brain invasion in the latter (p = 0.007). Thus, although pediatric and NF2-associated meningiomas share the common molecular alterations of their adult, sporadic counterparts, a higher fraction are genotypically and phenotypically aggressive. Given the high frequency of undiagnosed NF2 in the pediatric cases, a careful search for other features of this disease is warranted in any child presenting with a meningioma.

Cited by

• The FGF/FGFR System in the Biology and Therapeutic Landscape of Pediatric CNS Tumors
• Fluorescence in situ hybridization (FISH) in diagnostic and investigative neuropathology. [europepmc]
• Meningeal tumors of childhood and infancy. An update and literature review. [europepmc]
• Insights into meningioangiomatosis with and without meningioma: a clinicopathologic and genetic series of 24 cases with review of the literature. [europepmc]
• Meningothelial hyperplasia: a detailed clinicopathologic, immunohistochemical and genetic study of 11 cases. [europepmc]
• Evaluation of NF2 gene deletion in sporadic schwannomas, meningiomas, and ependymomas by chromogenic in situ hybridization. [europepmc]
• Neurofibromatosis type 2. [europepmc]
• Consensus recommendations to accelerate clinical trials for neurofibromatosis type 2. [europepmc]
• Gone FISHing: clinical lessons learned in brain tumor molecular diagnostics over the last decade. [europepmc]
• Long-term natural history of neurofibromatosis Type 2-associated intracranial tumors. [europepmc]
• Yes-associated protein 1 is activated and functions as an oncogene in meningiomas. [europepmc]
• Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review. [europepmc]
• A heritable form of SMARCE1-related meningiomas with important implications for follow-up and family screening. [europepmc]
• Glutamate metabolism in HIV-1 infected macrophages: Role of HIV-1 Vpr. [europepmc]
• First insight into the somatic mutation burden of neurofibromatosis type 2-associated grade I and grade II meningiomas: a case report comprehensive genomic study of two cranial meningiomas with vastly different clinical presentation. [europepmc]
• Molecular and translational advances in meningiomas. [europepmc]
• An update on the CNS manifestations of neurofibromatosis type 2. [europepmc]
• The CREB-binding protein inhibitor ICG-001: a promising therapeutic strategy in sporadic meningioma with NF2 mutations. [europepmc]
• Pediatric meningioma: a clinicopathologic and molecular study with potential grading implications. [europepmc]
• Age at Onset and Presenting Symptoms of Neurofibromatosis Type 2 as Prognostic Factors for Clinical Course of Vestibular Schwannomas. [europepmc]
• Molecular profiling of pediatric meningiomas shows tumor characteristics distinct from adult meningiomas. [europepmc]
• Ki67 Index Is the Most Powerful Factor for Predicting the Recurrence in Atypical Meningioma : Retrospective Analysis of 99 Patients in Two Institutes. [europepmc]
• Nervous system (NS) Tumors in Cancer Predisposition Syndromes. [europepmc]
• Meningiomas in patients with neurofibromatosis type 2 predominantly comprise 'immunogenic subtype' tumours characterised by macrophage infiltration. [europepmc]
• Novel Advances in Treatment of Meningiomas: Prognostic and Therapeutic Implications. [europepmc]
• Meningioma animal models: a systematic review and meta-analysis. [europepmc]

Related

• Molecular signatures define BAP1-altered meningioma as a distinct CNS tumor with deregulation of Polycomb repressive complex target genes
• Meningioangiomatosis Is Associated with Neurofibromatosis 2 but not with Somatic Alterations of the NF2 Gene
• European Association of Neuro-Oncology guideline on molecular testing of meningiomas for targeted therapy selection
• Insights into Gene Expression and the Influence of Regulatory Mechanisms within Meningioma - A Bioinformatic Approach
• The prognostic impact of CDKN2A/B hemizygous deletions in meningioma